Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and toxicity of docetaxel, gemcitabine and bevacizumab
combination, administered biweekly, as salvage treatment in patients with metastatic and HER2
negative breast cancer.